The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.35
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.10 (4.348%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2.35
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

23 Mar 2021 17:53

RNS Number : 2476T
Shield Therapeutics PLC
23 March 2021
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BYV81293

Issuer Name

SHIELD THERAPEUTICS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

USS Investment Management Ltd

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

NAME

CITY OF REGISTERED OFFICE

COUNTRY OF REGISTERED OFFICE

Universities Superannuation Scheme Ltd

London

United Kingdom

4. Details of the shareholder

Is the shareholder the same as the person subject to the notification obligation, above?

No

NAME

CITY OF REGISTERED OFFICE

COUNTRY OF REGISTERED OFFICE

Universities Superannuation Scheme Ltd

London

United Kingdom

5. Date on which the threshold was crossed or reached

19-Mar-2021

6. Date on which Issuer notified

23-Mar-2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

2.35%

0.00%

2.35%

5,067,985

Position of previous notification (if applicable)

3.98%

0.00%

3.98%

4,727,985

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

CLASS/TYPE OF SHARES ISIN CODE(IF POSSIBLE)

NUMBER OF DIRECT VOTING RIGHTS (DTR5.1)

NUMBER OF INDIRECT VOTING RIGHTS (DTR5.2.1)

% OF DIRECT VOTING RIGHTS (DTR5.1)

% OF INDIRECT VOTING RIGHTS (DTR5.2.1)

GB00BYV81293

5067985

0

2.350000

0.000000

Sub Total 8.A

5067985

2.350000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

TYPE OF FINANCIAL INSTRUMENT

EXPIRATION DATE

EXERCISE/CONVERSION PERIOD

NUMBER OF VOTING RIGHTS THAT MAY BE ACQUIRED IF THE INSTRUMENT IS EXERCISED/CONVERTED

% OF VOTING RIGHTS

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

TYPE OF FINANCIAL INSTRUMENT

EXPIRATION DATE

EXERCISE/CONVERSION PERIOD

PHYSICAL OR CASH SETTLEMENT

NUMBER OF VOTING RIGHTS

% OF VOTING RIGHTS

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate Controlling Person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Is there proxy voting?

No

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

23-Mar-2021

13. Place Of Completion

London, UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLJJMRTMTITBLB
Date   Source Headline
26th Jul 20192:05 pmRNSSecond Price Monitoring Extn
26th Jul 20192:00 pmRNSPrice Monitoring Extension
26th Jul 20197:00 amRNSFDA approves Feraccru® with a broad label
2nd Jul 201912:00 pmRNSAdditional Listing
13th Jun 20192:16 pmRNSResult of AGM
3rd Jun 20197:00 amRNSUpdate on Legal Proceedings
13th May 201912:00 pmEQSHardman & Co Research: Shield Therapeutics (STX): All in the execution
8th May 20197:00 amRNSAppointment of Joint Broker
2nd May 20197:00 amRNSInvestor presentation
1st May 201911:58 amRNSAdditional Listing
30th Apr 20197:00 amRNS2018 Annual Report and 2019 AGM Notice
26th Apr 20196:05 pmRNSPDMR Acquisition of Shares
24th Apr 20197:00 amRNSMajor extension to approval in Switzerland
17th Apr 20195:06 pmRNSGrant of share options
17th Apr 20195:01 pmRNSPDMR Acquisition of Shares and Additional Listing
17th Apr 20194:56 pmRNSPDMR Acquisition of Shares
11th Apr 20194:40 pmRNSHolding(s) in Company
8th Apr 20193:42 pmRNSAdditional Listing
3rd Apr 20197:00 amRNSFinal Results
1st Apr 20195:44 pmRNSAdditional Listing
1st Apr 201912:00 pmRNSChange of Adviser
27th Mar 20197:00 amRNSNotice of Results
14th Mar 20193:31 pmRNSPositive decision on Feraccru®'s process patent
4th Mar 20197:00 amRNSPositive results for Feraccru® in AEGIS-H2H study
29th Jan 20197:00 amRNSPositive results of AEGIS-CKD study
28th Jan 20197:15 amEQSHardman & Co Research: Shield Therapeutics (STX): Cast-iron investment
24th Jan 20197:00 amRNSBusiness and trading update
23rd Jan 201910:19 amRNSInvestor presentations
22nd Jan 20197:00 amRNSAppointment of Chairman
13th Dec 20187:00 amRNSUS New Drug Application PDUFA date for Feraccru
5th Dec 201810:04 amRNSUK launch of Feraccru® by Norgine
3rd Dec 20187:00 amRNSNew Drug Application for Feraccru®
9th Nov 20183:46 pmRNSHolding(s) in Company
8th Nov 20186:21 pmRNSHolding(s) in Company
1st Oct 20181:54 pmRNSNotification Of Major Holdings
1st Oct 20187:00 amRNSSubmission of an NDA for Feraccru® with the FDA
24th Sep 20181:06 pmRNSDirector/PDMR Shareholding
24th Sep 20181:02 pmRNSHolding(s) in Company
19th Sep 20187:14 amRNSLicence for the commercialisation of Feraccru
19th Sep 20187:12 amRNSInterim Results
13th Sep 20187:00 amRNSAEGIS-H2H Completion of Recruitment
26th Jul 20187:00 amRNSAppointment of Non-Executive Director
23rd Jul 20187:00 amRNSBusiness Update
9th Jul 20184:27 pmRNSHoldings in Company
9th Jul 20184:26 pmRNSHoldings in Company
28th Jun 201811:56 amRNSResult of AGM
28th Jun 20187:00 amRNSData from real-world clinical use of Feraccru
14th Jun 20187:00 amRNSPositive top-line results from AEGIS-PAED PK study
5th Jun 20187:00 amRNSDirectorate Change
5th Jun 20187:00 amRNS2017 Annual Report and 2018 AGM Notice

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.